Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.59 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | CALML3 | P27482 | 1/20 | 0.59 |
| ▸ | SDHA | P31040 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970856 | 0.90 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL13368068 | 0.86 | MAOB (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5810297 | 0.85 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL28110345 | 0.85 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL28428084 | 0.85 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1956748 | 0.85 | MAOB (0.82) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1954721 | 0.85 | MAOB (0.82) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1953314 | 0.85 | MAOB (0.82) | MAOBMAOALMNAPTGS1CALML3 | |
| Water SCHEMBL1953296 | 0.84 | MAOB (0.81) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14345304 | 0.83 | MAOB (0.70) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916567-B2 | Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof | UNIVERSAL TECHNOLOGY ALLIANCE, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20110136822-A1 | CERTAIN CRYSTALLINE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE THEREOF | UNIVERSAL TECHNOLOGY ALLIANCE, INC. | 2011-06-09 | — | — | US | disclosed |
| WO-2011054292-A1 | CERTAIN CRYSTALLINE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE THEREOF | SICHUAN BEILIKE BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136822-A1 | CERTAIN CRYSTALLINE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE THEREOF | ZYX, AQP3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOB 1038/4885MAOA 749/4885LMNA 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.